Pila Pharma AB (publ) (STO:PILA)
Sweden · Delayed Price · Currency is SEK 2.295
+0.165 (7.75%)
Jan 21, 2026, 5:29 PM CET
Pila Pharma AB Company Description
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden.
The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases.
Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.
Pila Pharma AB (publ)
| Country | Sweden |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Gustav Gram |
Contact Details
Address: Norra Vallgatan 72 Malmö, 211 22 Sweden | |
| Phone | 46 7 39 03 69 69 |
| Website | pilapharma.com |
Stock Details
| Ticker Symbol | PILA |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0015988274 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gustav Hanghoj Gram | Chief Executive Officer |
| Dorte Xenia Gram | Founder, Chairman and Chief Scientific Officer |
| Hampus Darrell | Chief Financial Officer |
| Miguel Lecumberri | Head of Compliance and Legal Affairs |
| Masoud Alavi | Head of Corporate Visual Communication |
| Andy Makin | Head of Toxicology |
| Maura McArdle | Head of BD and Quay Pharma |
| Mike Frodsham | Chief Technology Officer of Quay Pharma |
| Alison Foster | Head of Pre-Clinical - Quay Pharma |
| Simon Hamilton | Head of Global Business Development - Almac |